Taking Australian biotechnology to the world
Tuesday, 03 December, 2002
Australian Biotechnology News and Factiva, a Dow Jones and Reuters company, concluded an agreement this week that will see ABN's content distributed globally to over 1.5 million desktops.
Factiva provides business news services to more than 80 per cent of the 2002 Fortune Global 500 companies, including consulting, business services and research companies, pharmaceutical, medical and scientific organisations, as well as financial companies.
"That means every time we write about a local life science company or research institute, that report now has a global audience with immense investing and purchasing power," said IDG Life Sciences Group vice-president Andrew Birmingham. "Our mission has always been to take the Australian biotechnology story to the world. As we come to the end of 2002, this agreement takes us a long way towards that goal.
"As a result of our acquisition of Today's Life Science and the integration of its content with the biotechnews.com.au web site, we will also be distributing this content to the Factiva audience."
For more information about Factiva's customers, visit http://www.factiva.com/about/factivafacts.asp?node=corp2,
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
